Show Summary Details
Page of

The Syncardia Total Artificial Heart 

The Syncardia Total Artificial Heart
The Syncardia Total Artificial Heart

Steven Langford

and Francisco A. Arabía

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 January 2021

The 70-cc Syncardia TAH is the only device with FDA approval as a bridge to transplant in patients with biventricular failure, with a history that dates back to the earliest days of mechanical circulatory support. Clinical trials are currently underway to establish a destination therapy indication for the 70-cc device and a bridge to transplant indication for the 50-cc device. With the current heart allocation system in the United States, the TAH is the only dischargeable platform for patients who are listed as Status 2. Adverse events remain the primary limitation of these devices, and careful patient selection is critical for achieving excellent postoperative outcomes.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.